

...final call for abstracts...

7th International Symposium on Impact of Biotechnology on

# predictive oncology & intervention strategies

AUGUST 16-19, 2003

Montréal, Canada

Program at a Glance

PLENARY

SYMPOSIA

<b>AUGUST</b>	<b>Keynote Lectures</b>
16 <sup>th</sup>	<b>NATIONAL CANCER CONTROL PROGRAMS</b>
17 <sup>th</sup>	<b>DIET INFLUENCE IN ONCOGENESIS &amp; THERAPY</b>
18 <sup>th</sup>	<b>PREVENTION RESEARCH</b>
19 <sup>th</sup>	<b>TRANSLATIONAL RESEARCH</b>
18 <sup>th</sup> 19:00 h	<b>ROUNDTABLE ON PREVENTION</b>

BIOLOGY

PREVENTION

SCREENING

INTERVENTION

## Genomics & Proteomics

- Environmental risks cancer control
- Predisposition & gene expression
- Tobacco oncogenesis & nicotine metabolism
- Histone modification enzymes
- Nutritional genomics & epigenetics
- Circuitry of cancer

## Chronic Inflammation

- Cell mediated immunity & angiogenesis
- Premalignant chemoprevention
- HPV & neoplasia
- H. pylori* & gastric cancer
- Photocarcinogenesis & cutaneous melanoma
- Hepatitis B & C & hepatocellular carcinoma

## Preventive Strategies

- High-risk groups
- Smoking-related premalignant markers
- Molecular targets: prostate cancer
- Molecular targets: breast cancer
- Chemopreventive agents
- Vaccines

## Risk Avoidance & Reduction

- Tobacco control programs
- Environmental & genotoxic exposures
- Endocrine disrupters
- Physical activity & weight control
- Ionizing radiation exposure
- Sunscreens & skin cancer: education

## Challenges

- PAP smear screening: mid-income countries
- HPV-DNA-based programs
- VIA-based programs
- Public awareness & acceptance
- Health technology assessment
- Cancer surveillance, bioethics, legislation

## Controversies

- Lung screening
- Mammography, BSE, CBE
- Prostate-PSA testing
- Colorectal cancer screening
- Assessment of intraepithelial lesions
- High-risk vs asymptomatic population

## Strategies

- Signal transduction inhibitors, MDR
- Antioxidants: mitochondrial induced apoptosis
- Gap junctions targets & chemoprevention
- Tyrosine kinase inhibitors
- Topoisomerase inhibitors
- EGFR inhibitors

## Therapies

- Management of precursor lesions
- Immunotherapy of malignant melanoma
- Hematologic malignancies
- Stem cell gene therapy
- Combination therapy
- Vaccines

## Onco-genomics

- Genetic instability
- Pharmacogenomics
- Signaling pathways & expression
- Tumor suppressor genes
- Susceptibility genes
- Gene expression profiles

## Bio-oncology

- Stromal epithelial interactions
- Growth factors & signalling
- Angiogenesis & inhibition
- Carcinogen-detoxifying enzymes
- Immune surveillance & response
- Apoptosis mechanisms

## Environmental Cofactors

- Genetic & environmental interactions
- Occupational surveillance
- Diet (incl alcohol)
- Xenobiotic exposures
- Viral infections
- Physical activity & weight control

## Risk Assessment

- Altered nuclear organization & cancer
- Field effects in carcinogenesis
- Genetic predisposition
- Candidate gene associations
- Proteomic analysis of microdissected cells
- Organ-specific

## Predictive Markers

- Expression of *HER-2/neu*
- Chemotherapy response assays
- Predictive molecular pathology
- In vivo* imaging of protease activity
- Tumor-associated antigens
- Organ & tissue-specific

## Precursors

- Organ-specific
- Benign breast disease
- Prostate intraepithelial neoplasia
- Myelodysplastic syndromes
- Barrett esophagus
- Gastric epithelial dysplasia

## Strategies

- Chemoprevention drug development
- Synergistic therapies
- Differentiation therapy
- Telomerase identification & inhibitors
- Farnesyltransferase inhibitors
- Chronopharmacokinetics

## Modalities

- Vaccine trials
- Preventive oncology networks
- Psychosocial studies
- Health promotion education
- New roles in nursing oncology
- Palliative care

## Invited Faculty (partial listing)

DS Alberts, MD, University of Arizona, Tucson  
 Pierre R. Band, MD PhD, Health Protection Branch, Health Canada  
 Helmut Bartsch, PhD, DKFZ, Heidelberg  
 William T Beck PhD, University of Illinois, Chicago  
 Lukas Bubendorf, MD, Institute of Pathology, Basle  
 Angus G Dalgleish, MD, St Georges Hospital, London  
 Guy de Thé, MD PhD, Institut Pasteur, Paris  
 Eduardo L Franco, PhD DPH, McGill University  
 Hirota Fujiki, MD, Tokushima Bunri University  
 Adi F. Gazdar, MD, University of Texas, SWMC, Dallas  
 Parviz Ghadirian, PhD, CHUM, Montréal  
 William C Hahn MD PhD, Harvard Medical School  
 Susumu Ikehara MD PhD, Kansai Medical University  
 Henry T Lynch, MD, Hereditary Cancer Institute, Omaha  
 Anthony B. Miller, MB BChir, DKFZ, Heidelberg  
 Frank J Rauscher III, PhD, Wistar Institute, Philadelphia  
 Cecilia Sepulveda, MD, WHO, Cancer Control Program  
 Zongtang Sun, MD, National Lab Molecular Oncology, Beijing  
 Terrence Sullivan MD, Canadian Strategy for Cancer Control  
 Harry U. Vainio, MD, International Agency Research Cancer, Lyon  
 Th Van der Kwast MD, Erasmus University, Rotterdam

Jointly cosponsored by:



International Society for Preventive Oncology



WHO IARC



Santé Canada Health Canada



Stratégie canadienne de lutte contre le cancer



Institut national du cancer du Canada



action cancer ontario



McGill



Université de Montréal



Canadian Cancer Etiology Research Network

[www.cancerprev.org/meet](http://www.cancerprev.org/meet)

online registration • speakers list • program update

Please Post